DPP4 and diabetes mellitus: Recent evidence has revealed that the use of dipeptidyl peptidase-4 inhibitors (DPP4i), a common medication for type II diabetes mellitus (DM), is associated with BP development, namely DPP4i-associated BP (DPP4i-BP) (23–28).